Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors

The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced by the data submitted for the drug.